24 stycznia w Hotelu Airport Okęcie odbyło się coroczne spotkanie przedstawicieli mediów zaangażowanych w kwestie zdrowia ...

W tym tygodniu kluczową publikacją dla rynków finansowych będzie styczniowy raport payrolls z amerykańskiego rynku pracy.

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant lowered its 2024 full-year forecast. Monitor these key price levels.

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...

Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...

Eli Lilly's small pop was due to the latest developments in the lab reported by Novo Nordisk (NYSE: NVO), which, like the U.S. company, is doing brisk business with a weight loss drug: Wegovy ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...